{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:10:42Z","timestamp":1794305442623,"version":"4.9.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40744-023-00553-1","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T17:01:32Z","timestamp":1688403692000},"page":"1127-1146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis"],"prefix":"10.1007","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct01474512","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01597245","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01646177","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03073200","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02561806","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03573323","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01695239","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02349295","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03151551","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5110-3320","authenticated-orcid":false,"given":"Bruce W.","family":"Kirkham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Holzk\u00e4mper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khai Jing","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bolce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"issue":"5","key":"553_CR1","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","volume":"69","author":"PJ Mease","year":"2013","unstructured":"Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729\u201335.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"553_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-65.e19.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"553_CR3","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/j.1365-2133.2010.09831.x","volume":"163","author":"M Augustin","year":"2010","unstructured":"Augustin M, Reich K, Blome C, et al. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol. 2010;163(3):580\u20135.","journal-title":"Br J Dermatol"},{"issue":"2","key":"553_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/bjd.12354","volume":"169","author":"KM Klaassen","year":"2013","unstructured":"Klaassen KM, van de Kerkhof PC, Pasch MC. Nail psoriasis: a questionnaire-based survey. Br J Dermatol. 2013;169(2):314\u20139.","journal-title":"Br J Dermatol"},{"issue":"3","key":"553_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5114\/reum.2017.68912","volume":"55","author":"P Sobolewski","year":"2017","unstructured":"Sobolewski P, Walecka I, Dopytalska K. Nail involvement in psoriatic arthritis. Reumatologia. 2017;55(3):131\u20135.","journal-title":"Reumatologia"},{"issue":"2","key":"553_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000360696","volume":"229","author":"HMJ van der Velden","year":"2014","unstructured":"van der Velden HMJ, Klaassen KMG, van de Kerkhof PCM, Pasch MC. The impact of fingernail psoriasis on patients\u2019 health-related and disease-specific quality of life. Dermatology (Basel, Switzerland). 2014;229(2):76\u201382.","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"1","key":"553_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2005.07.073","volume":"57","author":"MM Jiaravuthisan","year":"2007","unstructured":"Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1\u201327.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"553_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1468-3083.2009.03363.x","volume":"23","author":"D McGonagle","year":"2009","unstructured":"McGonagle D. Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol. 2009;23(Suppl 1):9\u201313.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"553_CR9","first-page":"1315","volume":"33","author":"R Scarpa","year":"2006","unstructured":"Scarpa R, Soscia E, Peluso R, et al. Nail and distal interphalangeal joint in psoriatic arthritis. J Rheumatol. 2006;33(7):1315\u20139.","journal-title":"J Rheumatol"},{"issue":"4","key":"553_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1136\/annrheumdis-2011-200478","volume":"71","author":"ZR Ash","year":"2012","unstructured":"Ash ZR, Tinazzi I, Gallego CC, et al. Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. Ann Rheum Dis. 2012;71(4):553\u20136.","journal-title":"Ann Rheum Dis"},{"key":"553_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.723944","volume":"8","author":"SR Pennington","year":"2021","unstructured":"Pennington SR, FitzGerald O. Early origins of psoriatic arthritis: clinical, genetic and molecular biomarkers of progression from psoriasis to psoriatic arthritis. Front Med (Lausanne). 2021;8: 723944.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"553_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11926-020-00891-x","volume":"22","author":"A Zabotti","year":"2020","unstructured":"Zabotti A, Tinazzi I, Aydin SZ, McGonagle D. From psoriasis to psoriatic arthritis: insights from imaging on the transition to psoriatic arthritis and implications for arthritis prevention. Curr Rheumatol Rep. 2020;22(6):24.","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"553_CR13","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1080\/07853890.2022.2044511","volume":"54","author":"DK Lee","year":"2022","unstructured":"Lee DK, Lipner SR. Optimal diagnosis and management of common nail disorders. Ann Med. 2022;54(1):694\u2013712.","journal-title":"Ann Med"},{"issue":"6","key":"553_CR14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ad.2015.02.005","volume":"106","author":"I Raposo","year":"2015","unstructured":"Raposo I, Torres T. Nail psoriasis as a predictor of the development of psoriatic arthritis. Actas Dermosifiliogr. 2015;106(6):452\u20137.","journal-title":"Actas Dermosifiliogr"},{"issue":"3","key":"553_CR15","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/bjd.15831","volume":"178","author":"CI Busard","year":"2018","unstructured":"Busard CI, Nolte JYC, Pasch MC, Spuls PI. Reporting of outcomes in randomized controlled trials on nail psoriasis: a systematic review. Br J Dermatol. 2018;178(3):640\u20139.","journal-title":"Br J Dermatol"},{"issue":"8","key":"553_CR16","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.3899\/jrheum.201471","volume":"48","author":"GS Kaeley","year":"2021","unstructured":"Kaeley GS, Eder L, Aydin SZ, Rich P, Bakewell CJ. Nail psoriasis: diagnosis, assessment, treatment options, and unmet clinical needs. J Rheumatol. 2021;48(8):1208\u201320.","journal-title":"J Rheumatol"},{"issue":"6","key":"553_CR17","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40265-016-0564-5","volume":"76","author":"MC Pasch","year":"2016","unstructured":"Pasch MC. Nail psoriasis: a review of treatment options. Drugs. 2016;76(6):675\u2013705.","journal-title":"Drugs"},{"issue":"1","key":"553_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jaad.2019.01.072","volume":"81","author":"D Rigopoulos","year":"2019","unstructured":"Rigopoulos D, Baran R, Chiheb S, et al. Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus. J Am Acad Dermatol. 2019;81(1):228\u201340.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"553_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaad.2021.01.024","volume":"85","author":"IH Huang","year":"2021","unstructured":"Huang IH, Wu PC, Yang TH, et al. Small molecule inhibitors and biologics in treating nail psoriasis: a systematic review and network meta-analysis. J Am Acad Dermatol. 2021;85(1):135\u201343.","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"553_CR20","first-page":"adv00318","volume":"100","author":"J Szeb\u00e9nyi","year":"2020","unstructured":"Szeb\u00e9nyi J, Gede N, Hegyi PJ, et al. Efficacy of biologics targeting tumour necrosis factor-alpha, interleukin-17 -12\/23, -23 and small molecules targeting JAK and PDE4 in the treatment of nail psoriasis: a network meta-analysis. Acta Derm Venereol. 2020;100(18):adv00318.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"553_CR21","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1080\/09546634.2021.1892024","volume":"33","author":"K Reich","year":"2021","unstructured":"Reich K, Conrad C, Kristensen LE, et al. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. J Dermatol Treat. 2021;33(3):1652\u201360.","journal-title":"J Dermatol Treat"},{"issue":"4","key":"553_CR22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s13555-020-00383-x","volume":"10","author":"N Wasel","year":"2020","unstructured":"Wasel N, Tha\u00e7i D, French LE, et al. Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate-to-severe psoriasis: 52-week results from a phase 3, head-to-head study (IXORA-S). Dermatol Ther (Heidelb). 2020;10(4):663\u201370.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"553_CR23","first-page":"e911","volume":"35","author":"MMB Seyger","year":"2021","unstructured":"Seyger MMB, Reich A, Baou CE, et al. Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate-to-severe psoriasis: a post hoc analysis from IXORA-PEDS. JEADV. 2021;35:e911\u20133.","journal-title":"JEADV"},{"key":"553_CR24","doi-asserted-by":"publisher","first-page":"adv00787","DOI":"10.2340\/actadv.v102.2269","volume":"102","author":"A Egeberg","year":"2022","unstructured":"Egeberg A, Kristensen LE, Vender R, et al. Sustained resolution of nail psoriasis through 5 years with ixekizumab: a post hoc analysis from UNCOVER-3. Acta Derm Venereol. 2022;102:adv00787.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"553_CR25","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.19509","volume":"184","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184(6):1047\u201358.","journal-title":"Br J Dermatol"},{"issue":"1","key":"553_CR26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40744-021-00388-8","volume":"9","author":"LE Kristensen","year":"2022","unstructured":"Kristensen LE, Okada M, Tillett W, et al. Ixekizumab demonstrates consistent efficacy versus adalimumab in biologic disease-modifying anti-rheumatic drug-na\u00efve psoriatic arthritis patients regardless of psoriasis severity: 52-week post hoc results from SPIRIT-H2H. Rheumatol Ther. 2022;9(1):109\u201325.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"553_CR27","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1202a104","volume":"12","author":"K Reich","year":"2022","unstructured":"Reich K, Kristensen LE, Smith SD, et al. Efficacy and safety of ixekizumab versus adalimumab in biologic-na\u00efve patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomized SPIRIT-H2H Trial. Dermatol Pract Concept. 2022;12(2): e2022104.","journal-title":"Dermatol Pract Concept"},{"issue":"3","key":"553_CR28","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/bjd.16050","volume":"178","author":"KA Papp","year":"2018","unstructured":"Papp KA, Leonardi CL, Blauvelt A, et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018;178(3):674\u201381.","journal-title":"Br J Dermatol"},{"issue":"3","key":"553_CR29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/jdv.14033","volume":"31","author":"P van de Kerkhof","year":"2017","unstructured":"van de Kerkhof P, Guenther L, Gottlieb AB, et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31(3):477\u201382.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"553_CR30","doi-asserted-by":"crossref","unstructured":"van de Kerkhof P, Guenther L, Gottlieb AB, et al. Improvements in fingernail lesions in patients with moderate-to-severe psoriasis treated with ixekizumab versus placebo and etanercept: results from UNCOVER-2. J Am Acad Dermatol. 2016; 74(5): AB255","DOI":"10.1016\/j.jaad.2016.02.991"},{"issue":"9993","key":"553_CR31","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541\u201351.","journal-title":"Lancet"},{"key":"553_CR32","unstructured":"Ghislain P-D, Conrad C, Dutronc Y, et al. Comparison of ixekizumab and ustekinumab efficacy in the treatment of nail lesions of patients with moderate-to-severe plaque psoriasis: 24-week data from a phase 3 trial [abstract]. Arthritis Rheumatol. 2017;69(suppl 10). https:\/\/acrabstracts.org\/abstract\/comparison-of-ixekizumab-and-ustekinumab-efficacy-in-the-treatment-of-nail-lesions-of-patients-with-moderate-to-severe-plaque-psoriasis-24-week-data-from-a-phase-3-trial\/"},{"issue":"6","key":"553_CR33","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bjd.18851","volume":"182","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Papp K, Gottlieb A, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182(6):1348\u201358.","journal-title":"Br J Dermatol"},{"issue":"2","key":"553_CR34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/bjd.19147","volume":"183","author":"AS Paller","year":"2020","unstructured":"Paller AS, Seyger MMB, Alejandro Magari\u00f1os G, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183(2):231\u201341.","journal-title":"Br J Dermatol"},{"issue":"1","key":"553_CR35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"10086","key":"553_CR36","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317\u201327.","journal-title":"Lancet"},{"issue":"10","key":"553_CR37","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1136\/annrheumdis-2020-217372","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Mease P, Tahir H, et al. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis na\u00efve to biological disease-modifying antirheumatic drug: final results by week 52. Ann Rheum Dis. 2020;79(10):1310\u20139.","journal-title":"Ann Rheum Dis"},{"key":"553_CR38","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0655","author":"AS Paller","year":"2022","unstructured":"Paller AS, Seyger MMB, Magari\u00f1os GA, et al. Long-term efficacy and safety of up to 108 weeks of Ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial. JAMA Dermatol. 2022. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0655.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"553_CR39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3899\/jrheum.170429","volume":"45","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Gladman DD, Kishimoto M, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1). J Rheumatol. 2018;45(3):367\u201377.","journal-title":"J Rheumatol"},{"issue":"11","key":"553_CR40","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/rheumatology\/key182","volume":"57","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Combe B, Kremer JM, et al. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. Rheumatology (Oxford). 2018;57(11):2001\u201311.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"553_CR41","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1093\/rheumatology\/kez684","volume":"59","author":"V Chandran","year":"2020","unstructured":"Chandran V, van der Heijde D, Fleischmann RM, et al. Ixekizumab treatment of biologic-na\u00efve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). Rheumatology (Oxford). 2020;59(10):2774\u201384.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"553_CR42","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40744-020-00261-0","volume":"8","author":"AM Orbai","year":"2021","unstructured":"Orbai AM, Gratac\u00f3s J, Turkiewicz A, et al. Efficacy and safety of ixekizumab in patients with psoriatic arthritis and inadequate response to TNF inhibitors: 3-year follow-up (SPIRIT-P2). Rheumatol Ther. 2021;8(1):199\u2013217.","journal-title":"Rheumatol Ther"},{"key":"553_CR43","unstructured":"Reich K, Kristensen LE, Smith SD, et al. Ixekizumab shows early and sustained resolution of nail psoriasis in patients with psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from a multicentre, randomised, open-label, rater-blinded study (SPIRIT-H2H). European Academy of Dermatology and Venereology Congress. (2020)."},{"issue":"2","key":"553_CR44","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jaad.2020.11.022","volume":"85","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Lebwohl MG, Mabuchi T, et al. Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol. 2021;85(2):360\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"553_CR45","first-page":"958","volume":"15","author":"EB Dennehy","year":"2016","unstructured":"Dennehy EB, Zhang L, Amato D, Goldblum O, Rich P. Ixekizumab is effective in subjects with moderate to severe plaque psoriasis with significant nail involvement: results from UNCOVER 3. J Drugs Dermatol. 2016;15(8):958\u201361.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"553_CR46","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s13555-022-00704-2","volume":"12","author":"BE Elewski","year":"2022","unstructured":"Elewski BE, Blauvelt A, Gallo G, et al. Simultaneous nail and skin clearance in ixekizumab head-to-head trials for moderate-to-severe psoriasis and psoriatic arthritis. Dermatol Ther (Heidelb). 2022;12(4):911\u201320.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"553_CR47","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2018.06.039","volume":"80","author":"C Paul","year":"2019","unstructured":"Paul C, Griffiths CEM, van de Kerkhof PCM, et al. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study. J Am Acad Dermatol. 2019;80(1):70-9.e3.","journal-title":"J Am Acad Dermatol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00553-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00553-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00553-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T07:25:55Z","timestamp":1693380355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00553-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["553"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00553-1","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]},"assertion":[{"value":"22 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}